glp 1 discovery The GLP-1 revolution: What UAB researchers are discovering about how these drugs work History of glucagon-like peptide-1 receptor

A high extracellular glutamate concentration was one of the first xCT inhibitors described but a few years later, erastin (standing for eradicator of RAS and small T antigen-expressing cells) was identified by Stockwell's group in RAS-mutated cancer cell lines as inhibitor of xCT transport (42)

This substance offers multiple benefits related to the protection of the skin against damage, detoxification, and even brightening its tone due to high levels of melanin in the body

Thus, there is still a lack of evidence in treating human RA

Some patients who stop taking GLP-1s report that their cravings and the weight returns